• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

New math provides epiphany for measuring ROI


Disease management as we now define it may be on its last legs, though no one knows it yet. The Disease Management Purchasing Consortium has noticed that the savings in all but a few diseases doesn't offset the costs, and nowhere does it generate the level of return on investment (ROI) that some people think they are getting.

Ariel Linden's paper, "What Will It Take For Disease Management To Demonstrate A Return On Investment? New Perspectives On An Old Theme," proves that planwide rates for heart attacks, asthma attacks and other disease-specific avoidable events would have to fall by 20% or more just to break even on a DM program. Yet outside of heart failure fluid overload, I've seen 20% reductions achieved maybe one-fourth of the time-and that's what's needed to break even. Employers should use these event rates as a "plausibility test" to check the integrity of a financial ROI calculation. Oftentimes the reported financial ROI is so high that these disease-specific events would need to be wiped out in order to have achieved it in practice.

For those who think a health plan or vendor program is earning ROIs in excess of 3-to-1, I ask the simple question: "Have you run the plausibility test yet?" Ask, "If I'm supposedly saving all this money in, for example, cardiac and asthma disease management, then my total number of heart attacks and asthma attacks should be going way down, right?"

It's because in most diseases, some people who have the condition don't incur claims. Usually this is because they are mild cases-often so mild that they haven't been diagnosed yet. Claims algorithms will miss these mild cases, and because the missed cases have on balance much lower-than-average claims, the baseline will be set too high.

This can be called the "Bill Clinton Effect." Clinton probably had significant occlusion for years but had no diagnosis and incurred no meaningful claims during 2003. Then he needed an urgent bypass in 2004. If the baseline for a program in his health plan had been 2003, his zero claims in that year would have been left out of the baseline calculation. People who had heart attacks, bypasses and other diagnosed indications of heart disease in 2003 would have been in, but not undiagnosed people, even those who, like Clinton, were heart attacks waiting to happen.

Some might say his bypass would have been counted in 2004, raising that year's claims costs, so it evens out. Not so. While all the people with bypasses in 2003 would also have their much lower 2004 claims averaged into the contract period calculation, Clinton and others like him who had their bypasses counted in 2004 would not have had their much lower 2003 claims averaged into the baseline period calculation. It's not symmetrical, and therefore invalid.

The bad news is that it would seem like the demise of the field should be imminent as buyers run these plausibility tests and see the more accurate picture.


The good news for the DM industry is that just as organizations are figuring out that they are measuring wrong, a revolution from within is replacing this old model. The new model will bring far more impact, more easily measured for the buyers. For the vendors, this revolution promises actually to raise the prices they are able to charge, because finally they will be delivering true value without question.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.